The deal focuses on ARV-471, currently in phase 2 testing for advanced breast cancer patients whose tumours expresses oestrogen receptors – so are hormone sensitive – but test negative for ...

Arvinas’ most advanced programme is vepdegestrant (ARV-471), in phase 3 for hormone receptor-positive, HER2-negative breast cancer, which was licensed to Pfizer in 2021 for a massive $1 billion ...

ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was ...

and breast cancer (ARV-471), all in Phase 3 trials. Arvinas is also working on ARV-393 for B-cell malignancies, ARV-102 for brain diseases, and a KRAS G12D degrader still in lab testing.